Lanthio Pharma licenses lanthionine-stabilized Angiotensin agonistic peptide drug to Tarix Pharmaceuticals
Lanthio Pharma B.V. announced that it has granted Tarix Pharmaceuticals, Inc. an exclusive license to its lanthionine-stabilized Angiotensin-(1-7) agonistic peptide. The commercial terms contain milestone payments and royalties. Tarix will finance further product development.
Lanthionine-stabilized Angiotensin-(1-7) is being developed for the treatment of acute lung injury and related indications with high unmet medical need. It is an agonistic peptide that was discovered by Lanthio Pharma, using its proprietary LanthioPep® technology. The compound is stable and resistant to angiotensin-converting enzyme. Additionally, it has high specificity for the MAS receptor and shows increased intrinsic activity compared to wild-type Angiotensin-(1-7).
Bart Wuurman, CEO of Lanthio Pharma commented; This deal with Tarix presents an early revenue opportunity and further validates the exciting potential of our technology to discover next generation peptide therapeutics that are more stable and more potent than classical peptides and hence have the characteristics that are required for successful innovative therapeutics.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.